Nektar Therapeutics (0UNL.L)
USD 1.01
(-1.02%)
USD 1.01
(-1.02%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2023 | 230.4 Million USD | 75.22% |
| 2022 | 131.49 Million USD | -8.16% |
| 2021 | 143.17 Million USD | -4.73% |
| 2020 | 150.28 Million USD | -62.79% |
| 2019 | 403.93 Million USD | 63.57% |
| 2018 | 246.95 Million USD | 0.71% |
| 2017 | 245.2 Million USD | -1.36% |
| 2016 | 248.59 Million USD | 0.26% |
| 2015 | 247.94 Million USD | 85.52% |
| 2014 | 133.65 Million USD | 0.45% |
| 2013 | 133.04 Million USD | -2.6% |
| 2012 | 136.6 Million USD | -40.49% |
| 2011 | 229.53 Million USD | -1.05% |
| 2010 | 231.96 Million USD | -0.76% |
| 2009 | 233.75 Million USD | -0.66% |
| 2008 | 235.3 Million USD | -30.58% |
| 2007 | 338.96 Million USD | -22.63% |
| 2006 | 438.12 Million USD | -0.07% |
| 2005 | 438.41 Million USD | 120.24% |
| 2004 | 199.06 Million USD | -49.39% |
| 2003 | 393.3 Million USD | 18.46% |
| 2002 | 332.01 Million USD | 0.05% |
| 2001 | 331.86 Million USD | 3.62% |
| 2000 | 320.28 Million USD | 182.46% |
| 1999 | 113.39 Million USD | 2165.99% |
| 1998 | 5 Million USD | -3.49% |
| 1997 | 5.18 Million USD | 1196.25% |
| 1996 | 400 Thousand USD | -33.33% |
| 1995 | 600 Thousand USD | -14.29% |
| 1994 | 700 Thousand USD | 0.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2024 Q2 | 219.6 Million USD | -5.32% |
| 2024 Q1 | 231.93 Million USD | 0.67% |
| 2023 Q2 | 124.75 Million USD | -2.66% |
| 2023 Q3 | 121.28 Million USD | -2.78% |
| 2023 Q4 | 230.4 Million USD | 89.96% |
| 2023 Q1 | 128.16 Million USD | -2.54% |
| 2023 FY | 230.4 Million USD | 75.22% |
| 2022 Q4 | 131.49 Million USD | -2.34% |
| 2022 Q1 | 142.23 Million USD | -0.66% |
| 2022 FY | 131.49 Million USD | -8.16% |
| 2022 Q3 | 134.65 Million USD | -3.45% |
| 2022 Q2 | 139.46 Million USD | -1.95% |
| 2021 Q4 | 143.17 Million USD | -2.24% |
| 2021 FY | 143.17 Million USD | -4.73% |
| 2021 Q1 | 150.32 Million USD | 0.02% |
| 2021 Q2 | 148.43 Million USD | -1.26% |
| 2021 Q3 | 146.45 Million USD | -1.33% |
| 2020 Q4 | 150.28 Million USD | -2.64% |
| 2020 Q2 | 156.77 Million USD | -61.95% |
| 2020 Q3 | 154.37 Million USD | -1.53% |
| 2020 Q1 | 412.05 Million USD | 2.01% |
| 2020 FY | 150.28 Million USD | -62.79% |
| 2019 Q4 | 403.93 Million USD | 0.31% |
| 2019 FY | 403.93 Million USD | 63.57% |
| 2019 Q1 | 344.05 Million USD | 39.32% |
| 2019 Q2 | 346.39 Million USD | 0.68% |
| 2019 Q3 | 402.67 Million USD | 16.25% |
| 2018 Q4 | 246.95 Million USD | 0.18% |
| 2018 Q1 | 245.64 Million USD | 0.18% |
| 2018 Q3 | 246.51 Million USD | 0.18% |
| 2018 FY | 246.95 Million USD | 0.71% |
| 2018 Q2 | 246.07 Million USD | 0.18% |
| 2017 Q1 | 248.41 Million USD | -0.07% |
| 2017 FY | 245.2 Million USD | -1.36% |
| 2017 Q4 | 245.2 Million USD | -0.83% |
| 2017 Q3 | 247.25 Million USD | -0.34% |
| 2017 Q2 | 248.09 Million USD | -0.13% |
| 2016 Q3 | 247.51 Million USD | -0.57% |
| 2016 FY | 248.59 Million USD | 0.26% |
| 2016 Q2 | 248.93 Million USD | -0.52% |
| 2016 Q1 | 250.23 Million USD | 0.92% |
| 2016 Q4 | 248.59 Million USD | 0.44% |
| 2015 FY | 247.94 Million USD | 85.52% |
| 2015 Q1 | 134.79 Million USD | 0.86% |
| 2015 Q2 | 133.53 Million USD | -0.94% |
| 2015 Q3 | 132.21 Million USD | -0.98% |
| 2015 Q4 | 247.94 Million USD | 87.53% |
| 2014 Q3 | 130.33 Million USD | -0.52% |
| 2014 Q2 | 131.02 Million USD | -0.78% |
| 2014 Q1 | 132.05 Million USD | -0.75% |
| 2014 Q4 | 133.65 Million USD | 2.54% |
| 2014 FY | 133.65 Million USD | 0.45% |
| 2013 Q3 | 134 Million USD | -0.66% |
| 2013 Q1 | 135.76 Million USD | -0.62% |
| 2013 Q4 | 133.04 Million USD | -0.71% |
| 2013 FY | 133.04 Million USD | -2.6% |
| 2013 Q2 | 134.9 Million USD | -0.64% |
| 2012 Q1 | 228.84 Million USD | -0.3% |
| 2012 FY | 136.6 Million USD | -40.49% |
| 2012 Q4 | 136.6 Million USD | -0.59% |
| 2012 Q3 | 137.41 Million USD | -39.76% |
| 2012 Q2 | 228.12 Million USD | -0.31% |
| 2011 Q1 | 231.4 Million USD | -0.24% |
| 2011 FY | 229.53 Million USD | -1.05% |
| 2011 Q4 | 229.53 Million USD | -0.29% |
| 2011 Q3 | 230.2 Million USD | -0.27% |
| 2011 Q2 | 230.81 Million USD | -0.25% |
| 2010 Q1 | 233.3 Million USD | -0.19% |
| 2010 FY | 231.96 Million USD | -0.76% |
| 2010 Q3 | 232.35 Million USD | -0.21% |
| 2010 Q2 | 232.84 Million USD | -0.2% |
| 2010 Q4 | 231.96 Million USD | -0.17% |
| 2009 Q4 | 233.75 Million USD | -0.18% |
| 2009 Q2 | 234.57 Million USD | -0.16% |
| 2009 FY | 233.75 Million USD | -0.66% |
| 2009 Q1 | 234.94 Million USD | -0.15% |
| 2009 Q3 | 234.18 Million USD | -0.17% |
| 2008 Q1 | 338.58 Million USD | -0.11% |
| 2008 FY | 235.3 Million USD | -30.58% |
| 2008 Q2 | 337.84 Million USD | -0.22% |
| 2008 Q3 | 337.09 Million USD | -0.22% |
| 2008 Q4 | 235.3 Million USD | -30.2% |
| 2007 Q4 | 338.96 Million USD | -16.25% |
| 2007 FY | 338.96 Million USD | -22.63% |
| 2007 Q1 | 401.93 Million USD | -8.26% |
| 2007 Q2 | 401.76 Million USD | -0.04% |
| 2007 Q3 | 404.74 Million USD | 0.74% |
| 2006 FY | 438.12 Million USD | -0.07% |
| 2006 Q1 | 438.3 Million USD | -0.02% |
| 2006 Q4 | 438.12 Million USD | 0.01% |
| 2006 Q3 | 438.07 Million USD | -0.03% |
| 2006 Q2 | 438.19 Million USD | -0.03% |
| 2005 Q4 | 438.41 Million USD | -0.02% |
| 2005 Q1 | 196.3 Million USD | -1.39% |
| 2005 FY | 438.41 Million USD | 120.24% |
| 2005 Q2 | 194.89 Million USD | -0.72% |
| 2005 Q3 | 438.51 Million USD | 125.0% |
| 2004 Q2 | 205.89 Million USD | -4.02% |
| 2004 FY | 199.06 Million USD | -49.39% |
| 2004 Q4 | 199.06 Million USD | -0.14% |
| 2004 Q3 | 199.34 Million USD | -3.18% |
| 2004 Q1 | 214.52 Million USD | -45.46% |
| 2003 Q4 | 393.3 Million USD | -7.45% |
| 2003 Q3 | 424.98 Million USD | 3.45% |
| 2003 Q2 | 410.81 Million USD | 23.85% |
| 2003 Q1 | 331.69 Million USD | -0.1% |
| 2003 FY | 393.3 Million USD | 18.46% |
| 2002 Q4 | 332.01 Million USD | -0.13% |
| 2002 Q2 | 331.85 Million USD | 0.05% |
| 2002 Q1 | 331.67 Million USD | -0.06% |
| 2002 Q3 | 332.44 Million USD | 0.18% |
| 2002 FY | 332.01 Million USD | 0.05% |
| 2001 Q3 | 329.73 Million USD | 1.0% |
| 2001 Q4 | 331.86 Million USD | 0.65% |
| 2001 FY | 331.86 Million USD | 3.62% |
| 2001 Q1 | 318.91 Million USD | -0.43% |
| 2001 Q2 | 326.46 Million USD | 2.37% |
| 2000 Q2 | 242.63 Million USD | -0.82% |
| 2000 Q4 | 320.28 Million USD | 32.01% |
| 2000 Q1 | 244.64 Million USD | 115.76% |
| 2000 Q3 | 242.62 Million USD | -0.0% |
| 2000 FY | 320.28 Million USD | 182.46% |
| 1999 Q2 | 4.91 Million USD | -0.16% |
| 1999 Q3 | 4.9 Million USD | -0.26% |
| 1999 Q4 | 113.39 Million USD | 2212.19% |
| 1999 FY | 113.39 Million USD | 2165.99% |
| 1999 Q1 | 4.92 Million USD | -1.58% |
| 1998 Q4 | 5 Million USD | 0.95% |
| 1998 Q2 | 4.97 Million USD | -2.24% |
| 1998 FY | 5 Million USD | -3.49% |
| 1998 Q1 | 5.08 Million USD | -1.87% |
| 1998 Q3 | 4.95 Million USD | -0.34% |
| 1997 Q4 | 5.18 Million USD | 3403.38% |
| 1997 Q1 | 175 Thousand USD | -56.25% |
| 1997 FY | 5.18 Million USD | 1196.25% |
| 1997 Q2 | 162 Thousand USD | -7.43% |
| 1997 Q3 | 148 Thousand USD | -8.64% |
| 1996 Q3 | 200 Thousand USD | -33.33% |
| 1996 FY | 400 Thousand USD | -33.33% |
| 1996 Q1 | 300 Thousand USD | -50.0% |
| 1996 Q4 | 400 Thousand USD | 100.0% |
| 1996 Q2 | 300 Thousand USD | 0.0% |
| 1995 FY | 600 Thousand USD | -14.29% |
| 1995 Q1 | 400 Thousand USD | -42.86% |
| 1995 Q2 | 300 Thousand USD | -25.0% |
| 1995 Q3 | 300 Thousand USD | 0.0% |
| 1995 Q4 | 600 Thousand USD | 100.0% |
| 1994 FY | 700 Thousand USD | 0.0% |
| 1994 Q3 | 200 Thousand USD | -75.0% |
| 1994 Q4 | 700 Thousand USD | 250.0% |
| 1994 Q1 | 800 Thousand USD | 0.0% |
| 1994 Q2 | 800 Thousand USD | 0.0% |
| Name | Total Debt | Total Debt Difference |
|---|---|---|
| Dynavax Technologies Corporation | 256.91 Million USD | 10.32% |
| Walgreens Boots Alliance, Inc. | 9.55 Billion USD | 97.588% |
| Supernus Pharmaceuticals, Inc. | 41.52 Million USD | -454.822% |
| Perrigo Company plc | 4.07 Billion USD | 94.344% |
| Illumina, Inc. | 2.26 Billion USD | 89.814% |
| Thermo Fisher Scientific Inc. | 34.91 Billion USD | 99.34% |
| Iovance Biotherapeutics, Inc. | 1 Million USD | -22940.1% |
| IQVIA Holdings Inc. | 14.23 Billion USD | 98.381% |
| Heron Therapeutics, Inc. | 173.75 Million USD | -32.603% |
| Unity Biotechnology, Inc. | 26.99 Million USD | -753.653% |
| Waters Corporation | 2.35 Billion USD | 90.219% |
| Biogen Inc. | 7.33 Billion USD | 96.86% |
| Sangamo Therapeutics, Inc. | 38.1 Million USD | -504.664% |
| Evolus, Inc. | 126.54 Million USD | -82.069% |
| Adicet Bio, Inc. | 17.7 Million USD | -1201.48% |
| Esperion Therapeutics, Inc. | 540.94 Million USD | 57.408% |
| FibroGen, Inc. | 170.45 Million USD | -35.168% |
| Agilent Technologies, Inc. | 2.73 Billion USD | 91.576% |
| Homology Medicines, Inc. | 44.05 Million USD | -422.997% |
| Geron Corporation | 85.89 Million USD | -168.223% |
| Alnylam Pharmaceuticals, Inc. | 2.39 Billion USD | 90.392% |
| Editas Medicine, Inc. | 36.53 Million USD | -530.614% |
| Regeneron Pharmaceuticals, Inc. | 2.7 Billion USD | 91.476% |
| Amicus Therapeutics, Inc. | 445.05 Million USD | 48.231% |
| Cara Therapeutics, Inc. | 43.16 Million USD | -433.743% |
| bluebird bio, Inc. | 330.32 Million USD | 30.25% |
| Myriad Genetics, Inc. | 145 Million USD | -58.897% |
| Corbus Pharmaceuticals Holdings, Inc. | 20.88 Million USD | -1003.229% |
| BioMarin Pharmaceutical Inc. | 1.13 Billion USD | 79.68% |
| Viking Therapeutics, Inc. | 1.26 Million USD | -18185.794% |
| Anavex Life Sciences Corp. | - USD | -Infinity% |
| Intellia Therapeutics, Inc. | 115.34 Million USD | -99.748% |
| Zoetis Inc. | 6.8 Billion USD | 96.613% |
| Abeona Therapeutics Inc. | 4.4 Million USD | -5134.007% |
| Mettler-Toledo International Inc. | 2.16 Billion USD | 89.372% |
| Atara Biotherapeutics, Inc. | 57.87 Million USD | -298.122% |
| Vertex Pharmaceuticals Incorporated | 808.4 Million USD | 71.499% |
| Axsome Therapeutics, Inc. | 186.37 Million USD | -23.624% |
| Aclaris Therapeutics, Inc. | 3.07 Million USD | -7395.153% |
| Kala Pharmaceuticals, Inc. | 36.32 Million USD | -534.312% |
| Ionis Pharmaceuticals, Inc. | 1.45 Billion USD | 84.149% |
| Verastem, Inc. | 41.55 Million USD | -454.422% |
| OPKO Health, Inc. | 326.56 Million USD | 29.447% |
| Exelixis, Inc. | 189.94 Million USD | -21.299% |
| Imunon, Inc. | 1.13 Million USD | -20123.156% |
| Sarepta Therapeutics, Inc. | 1.39 Billion USD | 83.505% |
| uniQure N.V. | 138.4 Million USD | -66.464% |
| Neurocrine Biosciences, Inc. | 428.4 Million USD | 46.218% |
| Corcept Therapeutics Incorporated | 151 Thousand USD | -152483.444% |
| Halozyme Therapeutics, Inc. | 1.49 Billion USD | 84.632% |
| Blueprint Medicines Corporation | 774.12 Million USD | 70.237% |
| Insmed Incorporated | 1.2 Billion USD | 80.864% |
| Agios Pharmaceuticals, Inc. | 56.98 Million USD | -304.297% |
| TG Therapeutics, Inc. | 110.79 Million USD | -107.953% |
| Incyte Corporation | 38.28 Million USD | -501.773% |
| Emergent BioSolutions Inc. | 877.5 Million USD | 73.743% |